BioSpace News Archive

MOU to acquire 100% of privately held Sera Labs for $20 million, which consists primarily of stock with key earn out considerations totaling up to an additional $20 million within two years of completing the acquisition. Sera Labs brings to CURE a high-margin, retail and direct-to-consumer business with accelerating sales of its more than 20 products in the health & wellness, beauty, and pets categories and strong traction in both e-commerce and wholesale-to-retail distribution with to

Expanded role of Ms. Stafford as Chairman reflects the Board’s confidence in her leadership of the Company and strategic direction Renowned pharmaceutical executive Robert Ingram retiring as Executive Chair and remaining a member of Board of Directors MORRISVILLE, N.C., July 28, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced an expanded role of Paula Brown Stafford, President and Chief Executive Officer (“CEO”) of Novan, to als

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense oligonucleotide (ASO) therapies using its scalable PATrOL™ platform to address genetic diseases, today announced the appointment of industry veteran William Mann, Ph.D., MBA as chief operating officer (COO). Dr. Mann will leverage his decades of experience in the biopharma industry to manage NeuBase operations and adv

-- Building management team to support development and commercialization of innovative liquid biopsy tests, COLVERA ® , for colorectal recurrence monitoring, and TRIDENT, for colorectal screening -- BRIDGEWATER, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Clinical Genomics (“CG” or the “Company”), a provider of cancer diagnostic solutions, including liquid biopsy tests for screening and recurrence monitoring of colorectal cancer (CRC), today announced key appointments to its executive team: Mich

The Chief Executive Officer for BetterLife Pharma Inc., recently joined investor portal Proactive to discuss the successful trial of another interferon inhalation treatment for COVID-19 similar to BetterLife’s AP-003 product, what this trial means for BetterLife, and what advantages AP-003’s interferon alpha2b may have over interferon beta treatments.

Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not simply manage, disease, today announced the appointment of Michael H. Davidson, MD to its Board of Directors. Dr. Davidson, an industry leader and expert in preventative cardiology and lipidology, is the Founder and Chief Scientific Officer of Corvi

Builds upon previous $25M, five-year effort to advance Alzheimer’s research, care and support

DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, announced today the appointment of Bryan Laffitte , Ph.D., as Vice President, Biology. In his newly created role, Dr. Laffitte will be responsible for leading the company’s research and development

Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces the launch of the RI.HIP NAVIGATION for total hip arthroplasty (THA).

Recently, the Chinese Institute of Food Science and Technology brought together experts in Beijing to evaluate the results of a collaborative R&D effort between Infinitus Company Ltd. and Hangzhou Hunter Biotechnology Co., Ltd., named the Application of Zebrafish Efficacy and Safety Rapid Evaluation System in Health Food.